In the BioHarmony Drug Report Database
Umeclidinium
Incruse Ellipta, Rolufta, Rolufta Ellipta (umeclidinium) is a small molecule pharmaceutical. Umeclidinium was first approved as Incruse Ellipta on 2014-04-30. It is used to treat chronic bronchitis and pulmonary emphysema in the USA. It has been approved in Europe to treat chronic obstructive pulmonary disease. It is known to target muscarinic acetylcholine receptor M5, muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M1, muscarinic acetylcholine receptor M3, and muscarinic acetylcholine receptor M2. Anoro ellipta’s patents are valid until 2030-10-11 (FDA).
Trade Name
|
Rolufta, Rolufta Ellipta |
|---|---|
Common Name
|
umeclidinium |
ChEMBL ID
|
CHEMBL1187833 |
Indication
|
chronic bronchitis, chronic obstructive pulmonary disease, pulmonary emphysema |
Drug Class
|
Quaternary ammonium derivatives: muscarinic receptor antagonists |
Image (chem structure or protein)